Biomarkers of treatment response in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 14, Issue 2, 2014, Pages 165-172

  Buck, Dorothea ^a   Hemmer, Bernhard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

biomarker; multiple sclerosis; treatment response

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BIOLOGICAL MARKER; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; L SELECTIN; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; OLIGOCLONAL BAND; TERIFLUNOMIDE; VIRUS ANTIBODY;

DRUG SAFETY; HERITABILITY; HUMAN; JC VIRUS; MULTIFACTORIAL INHERITANCE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATIENT COMPLIANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84893107379     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.874289     Document Type: Review

References (93)

1. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74(24):2004-15
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47(6): 707-17
3. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: What is on the horizon? Ann Neurol 2007;62(4):314-26
4. Buck D, Hemmer B. Treatment of multiple sclerosis: Current concepts and future perspectives. J Neurol 2011;258(10): 1747-62
5. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253(1):98-108
6. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-Term trials. Neurology 2011;76(1 Suppl 1): S14-25
7. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302
8. Rocca MA, Messina R, Filippi M. Multiple sclerosis imaging: Recent advances. J Neurol 2013;260(3):929-35
9. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133(9):2592-602
10. Costello F, Hodge W, Pan YI, et al. Tracking retinal nerve fiber layer loss after optic neuritis: A prospective study using optical coherence tomography. Mult Scler 2008;14(7):893-905
11. Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007;69(22):2085-92
12. Petzold A, De Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: A systematic review and meta-Analysis. Lancet Neurol 2010;9(9): 921-32
13. Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler 2013;19(4):443-50
14. Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci 2008;29(Suppl 2): S211-13
15. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127(Pt 7):1463-78
16. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13): 938-52
17. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
18. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008;9(7):516-26
19. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-62
20. Teunissen CE, Tumani H, Bennett JL, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011;2011:246412
21. Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 1942;21(5):571-7
22. Joseph FG, Hirst CL, Pickersgill TP, et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009;80(3):292-6
23. Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001;124(Pt 11): 2169-76
24. Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 2008;3(7):e2559
25. Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70(13 Pt 2):1079-83
26. Zipoli V, Hakiki B, Portaccio E, et al. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler 2009;15(4): 472-8
27. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67(6):707-14
28. Saiz A, Carreras E, Berenguer J, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001;56(8):1084-9
29. Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986;163(1): 41-53
30. Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2008;79(10):1134-6
31. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998;4(3):111-17
32. Jarius S, Eichhorn P, Jacobi C, et al. The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity? J Neurol Sci 2009;280(1-2):98-100
33. Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 2009;4(11): E7638
34. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7
35. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-Aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66(5):617-29
36. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66(5):630-43
37. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10):1485-9
38. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-Term course of neuromyelitis optica. Brain 2008; 131(Pt 11):3072-80
39. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-Term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76(15): 1310-15
40. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71(3):314-22
41. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349(2):139-45
42. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66(6):833-42
43. Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008;71(15): 1142-6
44. Mclaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183(6): 4067-76
45. Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011; 17(3):297-302
46. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011;77(6): 580-8
47. Lolli F, Mulinacci B, Carotenuto A, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci USA 2005;102(29):10273-8
48. Lolli F, Mazzanti B, Pazzagli M, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 2005;167(1-2):131-7
49. Schwarz M, Spector L, Gortler M, et al. Serum anti-Glc(alpha1,4) Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006;244(1-2):59-68
50. Brettschneider J, Jaskowski TD, Tumani H, et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009;217(1-2):95-101
51. Querol L, Clark PL, Bailey MA, et al. Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology 2013;81(11): 956-63
52. Pandey S, Dioni I, Lambardi D, et al. Alpha actinin is specifically recognized by Multiple Sclerosis autoantibodies isolated using an N-glucosylated peptide epitope. Mol Cell Proteomics 2013;12(2):277-82
53. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204(10):2363-72
54. Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009; 106(20):8302-7
55. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23
56. Higashi K, Fujita A, Inanobe A, et al. An inwardly rectifying K(+) channel, Kir4.1, expressed in astrocytes surrounds synapses and blood vessels in brain. Am J Physiol Cell Physiol 2001;281(3):C922-31
57. Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012;135(Pt 6): 1819-33
58. Ayoglu B, Haggmark A, Khademi M, et al. Autoantibody profiling in multiple sclerosis using arrays of human protein fragments. Mol Cell Proteomics 2013;12(9):2657-72
59. Quintana FJ, Farez MF, Izquierdo G, et al. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 2012; 78(8):532-9
60. Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008; 275(1-2):7-17
61. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007; 69(14):1391-403
62. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65(1):33-9
63. Gneiss C, Reindl M, Berger T, et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 2004;24(5):283-90
64. Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study. Neurology 2009;73(18): 1493-500
65. Van Der Voort LF, Visser A, Knol DL, et al. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 2009;16(9): 1049-52
66. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009; 73(18):1485-92
67. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996; 47(4):889-94
68. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362(9391):1184-91
69. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68(13):977-84
70. Hemmer B, Stuve O, Kieseier B, et al. Immune response to immunotherapy: The role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005;4(7):403-12
71. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1. 0401 and HLA-DRB1. 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83(2):219-27
72. Buck D, Cepok S, Hoffmann S, et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68(4): 480-7
73. Weber F, Cepok S, Wolf C, et al. Single-nucleotide polymorphisms in HLAand non-HLA genes associated with the development of antibodies to interferon-beta therapy in multiple sclerosis patients. Pharmacogenomics J 2012;12(3):238-45
74. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361(11):1067-74
75. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: A cross-sectional and longitudinal study. Lancet Neurol 2010; 9(3):264-72
76. Rudick RA, O'connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-Treated patients. Ann Neurol 2010;68(3):304-10
77. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68(3):295-303
78. Plavina T, Subramanyam M, Bloomgren G, et al. Use of JC virus antibody index to stratify risk of progressive mutlifocal leukoencephalopathy in natalizumab-Treated patients with multiple sclerosis. Abstract ENS Congress 2013; 29 May - 1 June 2013, Orlando, FL, USA
79. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-Treated MS patients. Neurology 2013;81(10):865-71
80. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359): 214-19
81. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013;45: 1353-60
82. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol 2009;8(12):1111-19
83. Pappas DJ, Oksenberg Jr. Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy. Neurology 2010;74(Suppl 1):S62-9
84. Tumani H, Hartung HP, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009;35(2):117-27
85. Giovannoni G, Nath A. After the storm: Neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 2011; 76(14):1200-1
86. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-Acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72(15):1322-9
87. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76(14): 1206-13
88. Kuhle J, Malmestrom C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128(6):e33-6
89. Ehling R, Lutterotti A, Wanschitz J, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004;10(6):601-6
90. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002; 58(9):1372-81
91. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133(Pt 4): 1082-93
92. Martinez-Forero I, Pelaez A, Villoslada P. Pharmacogenomics of multiple sclerosis: In search for a personalized therapy. Expert Opin Pharmacother 2008;9(17):3053-67
93. Furlan R. Definition of non-responders: Biological markers. Neurol Sci 2008; 29(Suppl 2):S214-15